Polarean Imaging Share Discussion Threads

[global nomad] 18/9/2020 07:26

RNS this morning should keep the momentum going...

[aberloon2] 17/9/2020 08:55

There's a seller as well and yet the the share price heads north, don't know how much free float there is but this isn't normally what happens to my holdings, has some news leaked out?

[adorling] 16/9/2020 13:46

FDA submission must be getting close. Real momentum building since decisively breaking out to another ATH. Can see us welll pass 80p on FDA news?

[aberloon2] 16/9/2020 12:13

Wow, something happening?

[hedgehog 100] 12/9/2020 20:19

Definitely!

The chart has consolidated well at the circa 40p level, and now looks like it could be starting the next leg up.

In terms of newsflow, POLX's FDA submission is scheduled for this quarter, i.e. imminent.

[ali47fish] 12/9/2020 18:28

i am new to this and dicovered it through Amati vct- is this a good time to take a position from insightful long term investors please!

[aberloon2] 03/9/2020 08:14

Not selling these until the hoped for endgame, far too valuable...

[adorling] 02/9/2020 14:49

Good to see POLX back above 40p again - likely to see 39p act as solid support now so added a few more this morning ahead of FDA news.

[adorling] 18/8/2020 16:17

Powerful persistent breakout achieving ATH’s - there’s no doubt word from the clinical assessment Centres and Hospitals is spreading fast that this technology will transform imaging in the future for chest physicians and surgeons etc.

[aberloon2] 18/8/2020 12:08

This is my best medical share at the minute, no fuss, just goes up quietly.

[rhatton] 18/8/2020 11:54

Clear skies above and looking good

[loglorry1] 10/8/2020 14:08

Up again. Plenty more to go I think. I have top sliced some of the ones I paid 14p for but I'm happy to let the rest run as I think there is huge potential here.

[supernumerary] 07/8/2020 17:55

Maybe something to do with this:



NIH launches imaging AI collaboration for COVID-19 and beyond
by Conor Hale | Aug 6, 2020 10:27am

The National Institutes of Health is turning to artificial intelligence and imaging scans to not only help detect cases of COVID-19 earlier, but to potentially personalize treatments for the spreading disease.

In lung CT scans, the novel coronavirus leaves telltale signs that distinguish it from other respiratory diseases—small white spots and a slightly obscuring haze, described by radiologists as “ground glass,” that indicates fluid build-up and damage to the tissue. Abnormalities are found in the heart scans and ultrasounds of many COVID-19 patients as well.

A collaboration funded by the NIH’s National Institute of Biomedical Imaging and Bioengineering aims to develop new diagnostics and machine learning algorithms to quickly assess the severity of an infection and predict a person’s responses to different treatments.

“This program is particularly exciting because it will give us new ways to rapidly turn scientific findings into practical imaging tools that benefit COVID-19 patients,” NIBIB Director Bruce Tromberg said. “It unites leaders in medical imaging and artificial intelligence from academia, professional societies, industry and government to take on this important challenge.”

RELATED: Coronavirus tests the value of artificial intelligence in medicine

The resulting Medical Imaging and Data Resource Center will operate a large, open-source repository that will gather COVID-19 chest images from tens of thousands of patients, “allowing researchers to evaluate both lung and cardiac tissue data, ask critical research questions and develop predictive COVID-19 imaging signatures that can be delivered to healthcare providers,” said Guoying Liu, director of the NIBIB’s MRI program.

The database will be hosted at the University of Chicago, and co-led by a trio of medical imaging societies: the American College of Radiology, the Radiological Society of North America and the American Association of Physicists in Medicine.

In addition, the center will support five infrastructure development projects and oversee 12 research projects, covering about 20 university labs—all with an initial focus on COVID-19, but with plans to expand its imaging data services and AI development to other diseases in the future.

RELATED: To screen COVID-19 patients for heart problems, FDA clears several ultrasound, AI devices

“COVID-19 is our immediate target, but the MIDRC will ultimately enable the medical and scientific communities to mobilize images and data for work against other existing diseases and future healthcare threats,” said the University of Washington’s Paul Kinahan, chair of the AAPM’s research committee.

[acuere] 05/8/2020 15:06

Approaching new high. Hopefully the presentations on the first day of the conference are going down well.

[acuere] 30/7/2020 15:08

Price continues to progress within rising channel. This from today’s RNS.


“Many of the projects being presented at these two leading conferences have made use of Polarean's products to conduct research, highlighting the growing academic acceptance of the Company's technology. We hope that the inclusion of so many sessions on (129) Xenon will continue to showcase Polarean's important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system."

Hopefully FDA approval not far away.

[bobbybullet] 28/7/2020 23:35

No expedited FDA approval. Realisation this will take 12 months minimum. Patients will bring rewards but expect the price to drift in the meantime.

[solooiler] 28/7/2020 19:27

any thoughts why this is down so much today?

[hedgehog 100] 18/7/2020 20:54

"LSE % Gainers Top Lists
EPIC Name %
VRP Verona Pharma +118%"


Yesterday's top riser VRP illustrates the strong demand for quality lung healthcare shares at the moment:

17/07/2020 07:00 UKREG Verona Pharma plc Verona Pharma Raises $200 Million In Oversubscribed Private Placement And Subscription

"LONDON and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) -- Verona
Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma" or the "Company"),
a clinical-stage biopharmaceutical company focused on respiratory
diseases, announces it has raised approximately $200 million (GBP159
million*) in an oversubscribed private placement and subscription with
new and existing institutional and accredited investors (the
"Financing"). The Financing comprises a private placement of 39,090,009
of the Company's American Depositary Shares ("ADSs"), each representing
eight ordinary shares of the Company ("Ordinary Shares"), at a price of
$4.50 per ADS, and 43,111,112 of the Company's Ordinary Shares at the
equivalent price per Ordinary Share, being GBP0.45 or $0.5625 (together
the "Securities"). ...

Verona Pharma intends to use the net proceeds from the Financing
primarily to fund its Phase 3 clinical program ENHANCE (Ensifentrine as
a Novel inHAled Nebulized COPD thErapy) in chronic obstructive pulmonary
disease (COPD) and for general corporate purposes. The Phase 3 clinical
trials are planned to start later in 2020. ..."




With its enlarged equity VRP is now valued at £100s of millions, at its current share price of 101.5p.

But it still faces the hurdle of phase three clinical trials, which POLX passed in January of this year with flying colours.

[pauliewonder] 10/7/2020 13:33

Good rise here today and given the potential, this could well see new highs with a little momentum

[aberloon2] 10/7/2020 12:48

This heading to unchartered territory...

[idiot441] 08/7/2020 16:40

Each mm may have a 3p spread... but you can normally trade within that be cause more than one mm.

[emeraldzebra] 08/7/2020 16:04

why is the buy/sell spread on this so chronic ??

[hedgehog 100] 06/7/2020 17:23

It's interesting to compare POLX with AVCT, another COVID-19 play.

Coincidentally, both raise funds at a placing price of 18p this spring, within a few weeks of each other:

13/03/2020 12:51 UK Regulatory (RNS & others) Polarean Imaging PLC Conditional Fundraise to raise GBP8.4 million
"... GBP8.4 million (US$10.7 million) (before expenses) to be raised by means of a conditional fundraise (the "Fundraise") and the issue of, in aggregate 46,624,997 Fundraise Shares at 18 pence per Fundraise Share (the "Fundraise Price"). ..."


06/04/2020 07:00 UK Regulatory (RNS & others) Avacta Group PLC Proposed Placing to raise GBP3.75 million
"...the Company has today conditionally raised gross proceeds of GBP3.75 million pursuant to a placing (the "Placing") through the issuance of 20,833,333 new ordinary shares ("Ordinary Shares") at a price of 18 pence per share, being the same price as the Subscription. ..."


Since then AVCT has traded at over 200p per share, and is currently at 139p - a market cap. of £346M.

Compared to POLX at 33p - a market cap. of a mere £54M.

Although I would expect that to increase markedly this summer, with some key newsflow anticipated this quarter:
• New orders to be announced shortly (currently being finalised).
• FDA submission.
• FDA expediated review news within 45 days of submission.

And the closer we get to the FDA approval (effectively a licence to sell generally in the US), the more keenly will mass sales of POLX's technology be anticipated.

From a December 2018 Northland Capital broker note on POLX:
"“Polarean expects over US$500mln in system sales just to top-tier institutes,” said Alexandre in a note to clients."